Vaso Corporation CEO Reflects on a Year of Growth and Innovation in End-of-Year Letter Setting the Tone for a Promising 2025
Vaso (OTCQX: VASO), a company focused on human capital, information technology, and MedTech sectors, has released a shareholder and employee letter on December 16, 2024. The letter outlines the company's achievements throughout the year and presents strategic developments and priorities for 2025. The communication covers operational developments, product updates, financial performance, and thought-leadership initiatives, with details available on the company's website.
Vaso (OTCQX: VASO), un'azienda focalizzata sui settori del capitale umano, della tecnologia dell'informazione e della MedTech, ha pubblicato una lettera agli azionisti e ai dipendenti il 16 dicembre 2024. La lettera delinea i successi dell'azienda durante l'anno e presenta sviluppi strategici e priorità per il 2025. La comunicazione copre sviluppi operativi, aggiornamenti sui prodotti, performance finanziaria e iniziative di leadership di pensiero, con ulteriori dettagli disponibili sul sito web dell'azienda.
Vaso (OTCQX: VASO), una empresa centrada en los sectores de capital humano, tecnología de la información y MedTech, ha publicado una carta a los accionistas y empleados el 16 de diciembre de 2024. La carta describe los logros de la empresa a lo largo del año y presenta desarrollos estratégicos y prioridades para 2025. La comunicación abarca desarrollos operativos, actualizaciones de productos, desempeño financiero e iniciativas de liderazgo de pensamiento, con detalles adicionales disponibles en el sitio web de la empresa.
Vaso (OTCQX: VASO)는 인적 자원, 정보 기술 및 MedTech 부문에 초점을 맞춘 회사로, 2024년 12월 16일 주주 및 직원에게 편지를 발표했습니다. 이 편지는 회사의 올해 성과를 개요하고 2025년을 위한 전략적 개발 및 우선 순위를 제시합니다. 이 커뮤니케이션은 운영 개발, 제품 업데이트, 재무 성과, 사상 리더십 이니셔티브를 다루며, 추가 세부 사항은 회사 웹사이트에서 확인할 수 있습니다.
Vaso (OTCQX: VASO), une entreprise axée sur les secteurs du capital humain, des technologies de l'information et de la MedTech, a publié une lettre aux actionnaires et aux employés le 16 décembre 2024. La lettre décrit les réalisations de l'entreprise au cours de l'année et présente les développements stratégiques et les priorités pour 2025. La communication couvre les développements opérationnels, les mises à jour des produits, la performance financière et les initiatives de leadership éclairé, avec des détails supplémentaires disponibles sur le site internet de l'entreprise.
Vaso (OTCQX: VASO), ein Unternehmen, das sich auf die Bereiche Human Capital, Informationstechnologie und MedTech konzentriert, hat am 16. Dezember 2024 einen Brief an Aktionäre und Mitarbeiter veröffentlicht. Der Brief skizziert die Errungenschaften des Unternehmens im Laufe des Jahres und präsentiert strategische Entwicklungen sowie Prioritäten für 2025. Die Kommunikation umfasst betriebliche Entwicklungen, Produktaktualisierungen, finanzielle Leistungen und Initiativen zur Gedankenführung, mit weiteren Details, die auf der Unternehmenswebsite verfügbar sind.
- None.
- None.
| Vaso Corporation 137 Commercial Street Plainview, New York 11803 Tel: (516) 997-4600 Fax: (516) 997-2299 |
NEWS RELEASE
PLAINVIEW, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leader in human capital, information technology and MedTech, today released a letter to shareholders and employees summarizing the company’s achievements throughout the year and outlining key strategic developments and priorities for the upcoming year.
Highlights in the letter include operational developments, product updates, financial performance, and insights on thought-leadership initiatives. The goal is also to provide a business outlook and priorities for the year ahead.
To access the CEO Shareholder Letter, please visit: https://vasocorporation.com/category/news/
About Vaso Corporation
Headquartered in Plainview New York, Vaso Corporation is a leading human capital, information technology and MedTech business with a focus on healthcare professional sales services, network and IT services across sectors, and proprietary medical products. Vaso Corporation is a diversified organization with three core businesses operating as wholly-owned subsidiaries: VasoHealthcare, the professional sales service arm for GEHealthCare's diagnostic imaging and ultrasound products; VasoTechnology, an information technology and managed connectivity leader serving customers in healthcare provision and other sectors; and VasoMedical, the designer and manufacturer of proprietary medical devices including Biox series devices and the developer and operator of the ARCS cloud-based SaaS platform.
For additional information, please visit www.vasocorporation.com or contact us at
info@vasocorporation.
Investor Contacts:
Michael J. Beecher
Investor Relations
Phone: 516-508-5840
Email: mbeecher@vasocorporation.com
V&S Strategic Consulting ir@vasocorporation.com
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “optimistic”, “plans”, “potential”, “looking forward”, and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn in the US economy and the continued impact of the COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
# # #
FAQ
What key announcements did Vaso (VASO) make in their December 16, 2024 shareholder letter?
Where can investors access Vaso 's (VASO) 2024 end-of-year shareholder letter?
What business segments does Vaso (VASO) operate in as of 2024?
What trading platform is Vaso (VASO) listed on?
